Skip to main content

Table 1 Patient demographics and baseline characteristics before and after MAIC

From: Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective

Matching variable

Dl-3-n-butylphthalide

Edaravone dexborneol

Before MAIC

After MAIC

Effective sample size, n

2771

599

585

Mean age (SD), year

62.29 (11.54)

61.80 (9.46)

62.29

Male, n (%)

1890 (68.21%)

404 (67.45%)

68.21%

Mean intravenous medication time window (SD), hour

33.54(21.08)

28.01(10.96)

33.54

History of AIS, n (%)

791(28.55%)

174 (29.05%)

28.55%

Mean NHISS score (SD)

6.99(5.62)

7.07 (2.96)

6.99

Diagnosis with hypertension, n (%)

1871(67.52%)

390 (65.11%)

67.52%

Diagnosis with diabetes, n (%)

714 (25.77%)

151 (25.21%)

25.77%

Diagnosis with hyperlipidemia, n (%)

250(9.02%)

44(7.35%)

9.02%

  1. MAIC Matching-adjusted indirect comparison, mRS Modified Rankin scale, NIHSS National Institute of Health Stroke Scale, SD Standard deviation, AIS Acute ischemic stroke